Clovis Oncology Inc. (NASDAQ:CLVS) was up 3% on Tuesday . The company traded as high as $24.57 and last traded at $24.10, with a volume of 913,646 shares changing hands. The stock had previously closed at $23.39.

A number of research analysts have commented on CLVS shares. Piper Jaffray Cos. reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Sunday, May 8th. WallachBeth Capital lowered their price target on Clovis Oncology from $30.00 to $22.00 and set a “hold” rating for the company in a research report on Monday, May 9th. Zacks Investment Research lowered Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Vetr lowered Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 price target for the company. in a research report on Wednesday, May 25th. Finally, Credit Suisse Group AG reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Wednesday, June 8th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $30.48.

The firm has a 50 day moving average of $17.01 and a 200-day moving average of $16.34. The company’s market cap is $953.67 million.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.13) by $0.06. During the same period in the previous year, the business posted ($2.10) EPS. Analysts forecast that Clovis Oncology Inc. will post ($9.33) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Clovis Oncology stock. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.09% of Clovis Oncology as of its most recent filing with the SEC.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.